$3,000.00
Big Pharma is poised for growth due to strong launch portfolios, the availability of high-potential pipeline assets, and companies’ sharpened focus on high-performing markets.
Big Pharma is poised for growth due to strong launch portfolios, the availability of high-potential pipeline assets, and companies’ sharpened focus on high-performing markets. Using in-house sales forecasts, this analysis explores and visualizes market dynamics in the Big Pharma peer set out to 2024. Using the analysis of more than 700 products from the portfolios of 16 companies in the pharmaceutical industry, Datamonitor Healthcare forecasts that the Big Pharma peer set will add $60bn in sales, generating $499bn out to 2024. By delving deeper into drivers of strategy, revenue trends, and therapy area focus, this analysis is vital to understanding how the peer set will navigate headwinds in order to steer towards robust growth.
This analysis assesses Datamonitor Healthcare’s Big Pharma peer set over the 2014–24 forecast period. The companies included in this peer set include:
AbbVie
Amgen
Bristol-Myers Squibb
Eli Lilly
Johnson & Johnson
Merck & Co
Pfizer
AstraZeneca
Bayer
Boehringer Ingelheim
GlaxoSmithKline
Novartis
Novo Nordisk
Roche
Sanofi
Teva
LIST OF FIGURES
5 EXECUTIVE SUMMARY
5 Scope of Datamonitor’s coverage of the orphan drug sector
7 Key findings
8 Definition of an orphan drug
8 Orphan drug market analysis, 2011–17
9 Orphan drug key companies
11 MARKET ANALYSIS
11 Key findings
11 Introduction
12 Orphan drug market size, 2005–17
32 COMPANY ANALYSIS
32 Key findings
33 Introduction
34 Novartis
36 Johnson & Johnson
38 Sanofi
40 Pfizer
42 AstraZeneca
43 Celgene
45 Allergan
46 Shire
48 UCB
49 Alexion
49 BioMarin
51 NPS Pharmaceuticals
52 Vertex
54 APPENDIX
54 References
55 Exchange rates
8 Figure 1: Orphan drug sales, by peer set ($m), 2011–17
10 Figure 2: Net orphan drug sales difference, by company ($m), 2011–17
12 Figure 3: Orphan drug market size ($m), 2005–17
21 Figure 4: Orphan drug sales, by therapy area ($m), 2011–17
24 Figure 5: Orphan drug sales, by molecule type ($m), 2011–17
25 Figure 6: Orphan drug sales, by peer set ($m), 2011–17
27 Figure 7: Net orphan drug sales difference, by company ($m), 2011–17
LIST OF TABLES
5 Table 1: Datamonitor’s orphan drug market company coverage
15 Table 2: Top 20 brands with an orphan drug approval by the FDA
18 Table 3: Orphan drugs therapy area sales ($m), 2011–17
23 Table 4: Orphan drug sales, by molecule type ($m), 2011–17
29 Table 5: Key orphan disease players as acquisition targets for major pharma companies
33 Table 6: The leading pharmaceutical companies in the orphan drug arena
55 Table 7: Exchange rates, 2012
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!